Loading…
Reliance Pharma Fund
Disclosed for 84 months, Sep 2012 to Aug 2019. This scheme is no longer reporting.Published as: RELIANCE PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹1,235 Cr
down ₹133 Cr vs Apr 2017
- Stocks held
Reliance Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In May 2017 it disclosed 15 stocks worth ₹1,235 Cr, down ₹133 Cr from Apr 2017. Its largest positions were Aurobindo Pharma Limited (9.5%), Divi's Laboratories Limited (9.4%), Dr. Reddy's Laboratories Limited (9.2%); the ten largest together made up 81.9% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 85.3% of its equity. Cash and debt stood at 1.0%. Compared with Apr 2017 the fund entered 0 new stocks and exited 2.
Against 227 other Sectoral / Thematic funds
Concentration
99%
Top-10 weight is higher than 99% of peers
Breadth
2%
Holds more stocks than 2% of peers
Cash
13%
Holds more cash than 13% of peers
What these mean: concentration · cash
Holdings in May 2017
Download CSVEvery line the fund disclosed, with the change against Apr 2017. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Aurobindo Pharma Limited | 9.53% | up 0.44 pts | ₹118 Cr | down ₹6.7 Cr | Trimmed |
| Divi's Laboratories Limited | 9.43% | up 2.28 pts | ₹116 Cr | up ₹18.7 Cr | Added |
| Dr. Reddy's Laboratories Limited | 9.21% | up 1.60 pts | ₹114 Cr | up ₹9.6 Cr | Added |
| Abbott India Limited | 9.14% | up 0.41 pts | ₹113 Cr | down ₹6.5 Cr | Trimmed |
| Zydus Lifesciences Limited | 8.64% | down 1.65 pts | ₹107 Cr | down ₹34.1 Cr | Trimmed |
| Sanofi India Limited | 8.37% | up 0.62 pts | ₹103 Cr | down ₹2.7 Cr | Trimmed |
| Lupin Limited | 8.27% | up 1.43 pts | ₹102 Cr | up ₹8.5 Cr | Added |
| Sun Pharmaceutical Industries Limited | 7.31% | up 0.04 pts | ₹90.3 Cr | down ₹9.2 Cr | Trimmed |
| Cipla Limited | 6.27% | down 0.24 pts | ₹77.5 Cr | down ₹11.7 Cr | Trimmed |
| Thyrocare Technologies Limited | 5.73% | down 1.08 pts | ₹70.7 Cr | down ₹22.4 Cr | Trimmed |
| Max India Limited | 4.82% | up 0.07 pts | ₹59.5 Cr | down ₹5.5 Cr | Trimmed |
| Healthcare Global Enterprises Limited | 4.05% | down 0.78 pts | ₹50 Cr | down ₹16 Cr | Trimmed |
| Glenmark Pharmaceuticals Limited | 3.28% | down 0.97 pts | ₹40.6 Cr | down ₹17.6 Cr | Trimmed |
| IPCA Laboratories Limited | 2.78% | down 0.28 pts | ₹34.3 Cr | down ₹7.5 Cr | Trimmed |
| Torrent Pharmaceuticals Limited | 2.15% | down 0.08 pts | ₹26.5 Cr | down ₹4 Cr | Trimmed |
| Cash, TREPS & receivables | 1.01% | up 0.37 pts | ₹12.4 Cr | up ₹3.8 Cr | Added |
What changed, Apr 2017 to May 2017
New New positions (0)
None.
Exited Exited (2)
- Apollo Hospitals Enterprise Limitedwas 1.6% · ₹21.6 Cr
- Narayana Hrudayalaya Limitedwas 0.6% · ₹8.3 Cr
Added Biggest additions
- Divi's Laboratories Limitedup ₹18.7 Cr (+2.28% pts)
- Dr. Reddy's Laboratories Limitedup ₹9.6 Cr (+1.60% pts)
- Lupin Limitedup ₹8.5 Cr (+1.43% pts)
Biggest reductions
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Apr 2017, the weight rose most in Pharmaceuticals & Biotechnology (+3.9 pts), and fell most in Healthcare Services (−3.9 pts).
- Pharmaceuticals & Biotechnology81.3% → 85.3%+3.9 pts
- Healthcare Services18.7% → 14.7%−3.9 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | May 2014 | May 2016 | Nov 2016 | Feb 2017 | Apr 2017 | May 2017 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 94.8% | 93.3% | 84.3% | 84.9% | 81.3% | 85.3% |
| Healthcare Services | — | 5.0% | 15.7% | 15.1% | 18.7% | 14.7% |
Allocation in May 2017change vs Apr 2017
- Pharmaceuticals & Biotechnology (12)85.3%▲ 3.9 pts
- Healthcare Services (3)14.7%▼ 3.9 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, May 2017
1.0%
▲ 0.4 pts vs Apr 2017
- Cash alone
- 1.0%
- cash and net receivables
- A year earlier
- 1.1%
- May 2016 · now ▼ 0.1 pts
- Last 12 months
- 0.4% – 3.6%
- lowest to highest · record 9.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.